What is ReceptivaDx?

ReceptivaDx is the only test that can identify endometriosis, progesterone resistance and endometritis in a single sample. ReceptivaDx  includes BCL6, a marker that identifies uterine inflammation most often associated with asymptomatic (silent) endometriosis. BCL6 is found in more than 50% of women with unexplained infertility and 65% of women with two or more IVF failures. The ability to identify progesterone resistance via the BCL6 marker has been previously linked in published data to both implantation failure and recurrent pregnancy loss. Progesterone resistance is a condition that causes unfavorable changes on the uterine lining blocking the important hormone progesterone from carrying out its vital role preparing the lining for embryo survival. Finally, ReceptivaDx can also be used to identify endometritis (chronic bacterial infection of the uterine lining) via the addition of our CD138 marker. The good news for providers and patient is that a positive BCL6 or CD138 result both have effective treatment options, significantly improving chances for a live birth.

If the test results are positive, it indicates a high level of BCL6, identifying the presence of uterine lining inflammation, most often associated with endometriosis. If the test results are negative, it suggests a high likelihood that no inflammation is present, Either results are useful to you and your physician because they narrow down potential courses of action, increasing your chances of a successful live birth.

How can the ReceptivaDx test help me?

If endometriosis goes untreated, issues with fertility are likely to persist, even throughout IVF treatment. Women who test positive for BCL6 and left untreated are 5 times less likely to succeed in IVF than women who test negative. 

If  positive,  there are two courses of action that have proven effective in thousands of IVF patients; hormone treatment to suppress the inflammation or laparoscopic surgery to remove the problematic tissue. Removing endometriosis around the endometrial lining has also  proven to increase the  chances of conception even without IVF.

A negative BCL6 test result provides the reassurance that endometriosis is not a current concern and that future attempts at pregnancy are more likely to be successful.

While other tests evaluate the quality of embryos or determine optimal embryo transfer windows, only ReceptivaDx™ can accurately detect inflammatory conditions on the uterine lining likely to cause implantation issues. If you have experienced infertility, ReceptivaDx test results can give you peace of mind, a clear plan for treatment, and renewed chances of a successful pregnancy.

ReceptivaDx™ (BCL6 Test) Predicts Chances for a Successful Transfer and Successful Pregnancy

In a study published in the December 2017 issue of Fertility & Sterility, the official journal of the American Society of Reproductive Medicine (ASRM), BCL6 was able to identify women with a poor prognosis for IVF success and a successful pregnancy if left undetected and untreated.  Endometrial BCL6 testing for the prediction of in vitro fertilization outcomes: a cohort study. Almquist LD, Likes CE, Stone B, Brown KR, Savaris R, Forstein DA, Miller PB, Lessey BA Fertil Steril. 2017 Dec;108(6):1063-1069

Women testing positive for ReceptivaDx (BLC6) without treatment:

  • Less than 11% Success rate resulting in live birth

Women testing negative for ReceptivaDx (BLC6):

  • More than 59% Success rate resulting in live birth

Without treatment, women testing positive are 5 times less likely to succeed in IVF.

Frequently Asked Questions

ReceptivaDx is a first of its kind test for the detection of inflammation of the uterine lining most commonly associated with endometriosis, a leading cause of infertility and implantation failure.

Women testing positive for ReceptivaDx are 5 times less likely to succeed in IVF than women testing negative.

ReceptivaDx (BCL6 Test) Predicts Chances for a Successful Transfer and Successful Pregnancy.

Candidates for ReceptivaDx testing include

  • All women with unexplained infertility
  • Women who have failed one or more IVF cycles
  • Women with limited embryo reserves
  • Women who have experienced recurrent pregnancy loss
  • Women who cannot afford IVF or that have limited fertility coverage

Undetected endometriosis interferes with the ability of a fertilized egg to implant. Endometriosis can block successful implantation regardless of how a woman gets pregnant, through normal sexual intercourse or IVF. While many patients hear about endometriosis in women who have experienced pelvic pain, painful intercourse or heavy bleeding during menses, milder forms without symptoms (Silent endometriosis) can be present without experiencing any physical symptoms. These milder forms of endometriosis are often undetectable and cannot always be visualized through ultrasound or laparoscopy. This is the power and benefit to patients by having the ReceptivaDx test performed.

The ReceptivaDx Test is performed using an endometrial biopsy sample, a routine procedure that can be performed during a normal office visit with your Ob-Gyn or Reproductive Specialist. The biopsy can be taken during a natural or mock cycle, but must be taken during the window of implantation.

Defining Your ReceptivaDx Biopsy Date Range

Natural Cycle:
7-10 days after ovulation occurs

Mock Cycle:
6-10 days after start of progesterone

Once collected, the sample is placed in a preservative (10% formalin vial) and is sent overnight via FedEx to our testing facility. Upon arrival, biopsies are processed and evaluated by our pathology team. A full pathology report is then prepared and submitted to your physician. Results are usually available in 5-6 business days. Samples are stable at room temperature during the entire shipping process and can be collected any day of the week. Our ReceptivaDx Collection Kit comes complete with everything necessary to properly collect and submit a sample.

The ReceptivaDx test was originally validated in natural cycle biopsies collected 7-10 days after ovulation. The natural cycle biopsy provides a significantly lower expense to the patient by removing the need for costly medications used in mock cycle biopsies.

If a mock cycle biopsy is preferred by your provider, ReceptivaDx has now been analyzed in over 15,000 mock cycle biopsies and can be performed safely without concern. Providers are reminded that 5 full days of progesterone administration (120 hours) must be onboard to obtain accurate results. Chances of a false negative can occur if protocols are not properly followed. While other endometrial biopsy tests for timing purposes suggest day 5 biopsies in their protocols, we recommend day 6 or day 7 at the earliest to obtain an accurate BCL6 result.

Unfortunately, the BCL6 marker was not validated during egg retrieval cycles and should not be obtained in that same cycle. Biopsy at the time of egg retrieval, while convenient for the provider and patient, occurs too early in the cycle to detect the presence of BCL6. Medications used during the egg retrieval cycle could impact results and do not represent an accurate portrayal of the uterine lining during an embryo transfer or natural cycle. It is suggested to wait until the next cycle after the egg retrieval cycle to obtain an optimal biopsy.

The cost of the ReceptivaDx test (BCL6 and full pathology report only) is $690 dollars. This includes overnight shipping costs via FedEx to our nearest licensed testing center. Additional markers can be added. CD138, a marker that identifies endometritis can be ordered for an additional $145.

Cicero Diagnostics requires payment via credit card at the time of sample submission. If preferred, patients may call our offices to make payment in advance. Cicero Diagnostics provides a detailed receipt that can be used for potential reimbursement from insurance or healthcare spending accounts. Please provide an email address on the test request form to receive the detailed receipt.

International customers should contact us directly at info@cicerodx.com or call us at 1-714-951-9245 for detailed information.

If found to be positive for BCL6, endometriosis is likely. A treatment plan involving hormone therapy or laparoscopy to remove visible endometriosis can correct the situation. Patients undergoing 60 days of hormone therapy have shown excellent success in achieving pregnancy and live births by hundreds of our  IVF centers. A recently published 7-year study shows the impact of these treatment modalities on live birth rates with women with unexplained infertility and positive BCL6 results.

Any fertility center or Ob-Gyn office performing endometrial biopsies can collect a sample for ReceptivaDx testing. A list of fertility centers offering ReceptivaDx routinely to their patients can be found here. If you need additional help finding a center near you, please contact our customer service desk at 800-795-5385. Collection kits are provided to physician offices at no-charge. We can also arrange shipments of collection kits for patients to bring into offices that don’t currently stock our kits. 

Cicero Diagnostics, Inc. is a diagnostics company dedicated to the advancement of clinical assays in women’s healthcare. Cicero Diagnostics has exclusive rights to BCL6 analysis on endometrial tissue. Our company has forged relationships with key academic research centers and is dedicated to the development of new testing modalities for endometriosis and unexplained infertility.

Cicero Diagnostics maintains two laboratory locations in the US. Both testing sites operate under CLIA guidelines established for best laboratory practices and are fully licensed. CiceroDx is the only licensed provider in the US for detection of the BCL6 marker in endometrial biopsy samples.

Please feel free to contact us at 800-795-5385 for further information. International clients can email us at info@cicerodx.com or call us at 1-714-951-9245.

Get Started

Get started and get answers. Find a center near you with our locator map. Questions? Call us for a free phone consultation. We’re here to help.